Tevimbra plus chemotherapy reduced the risk of death by 20% compared with placebo plus chemotherapy. The Food and Drug Administration (FDA) has approved Tevimbra ® (tislelizumab-jsgr) for use in ...

The transition from the esophagus to the stomach is a delicate region from a medical point of view, often associated with pathological disorders leading to cancer. An international research team has ...

Chinese biopharma Hutchmed today announces that the New Drug Application (NDA) for savolitinib for the treatment of locally ...

Opdivo was approved by the FDA for use if disease persisted after neoadjuvant chemoradiotherapy in these patients, which is “exciting news,” as patients would typically undergo surveillance when this ...

Credit: Astellas. Vyloy is a claudin 18.2-directed cytolytic antibody. In clinical trials, CLDN18.2 positivity was determined by immunohistochemistry on gastric or GEJ tumor tissue specimens with the ...

The FDA approved nivolumab as adjuvant treatment for certain patients with completely resected esophageal or gastroesophageal junction cancers, according to the agent’s manufacturer. The approval ...

Please provide your email address to receive an email when new articles are posted on . Sintilimab plus chemotherapy conferred longer median OS compared with placebo plus chemotherapy. Patients with ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Samuel J. Klempner ...

SAN MATEO, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S.

Cancers of the upper gastrointestinal (GI) tract form a heterogeneous group of diseases for which treatment paradigms for localized disease continue to emerge. The management for localized disease is ...

Esophageal cancer causes more than half a million deaths each year. Neoadjuvant chemoradiotherapy followed by surgery is a widely used standard of care in resectable, locally advanced esophageal or ...